Company intelligence / Profile preview

Biogaran

Ownership: Private
Employees: ~750
Development stage: Commercial

Overview

Biogaran leads the French generic drug market with over 300 million boxes sold annually. It has expanded into biosimilars since launching its first in February 2015. The company’s portfolio covers both retail and hospital markets with approved generics and biosimilars targeting major chronic diseases such as hypertension, diabetes, and cardiovascular conditions. Clinical results are consistent with regulatory standards for bioequivalence.

Therapeutic areas: Metabolic DisordersPulmonologyCardiovascularEndocrinology
Modalities: Small moleculesBiosimilars (biological drugs)
Industry: Biotech

Drug pipeline

1 asset

Triveram

Commercial

Indications: Cardiovascular disease

Partnerships

ROVI – partnership to market enoxaparin biosimilar in France

Beyond the preview

Go deeper on Biogaran.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biogaran.

Explore the full profile